ValuEngine lowered shares of Diplomat Pharmacy (NYSE:DPLO) from a buy rating to a hold rating in a research report report published on Saturday morning, ValuEngine reports.

Several other equities research analysts also recently weighed in on DPLO. William Blair downgraded shares of Diplomat Pharmacy from a market perform rating to an underperform rating in a research note on Friday, February 22nd. JPMorgan Chase & Co. downgraded shares of Diplomat Pharmacy from an overweight rating to a neutral rating and reduced their target price for the company from $9.00 to $8.00 in a research note on Friday, February 22nd. Mizuho set a $8.00 target price on shares of Diplomat Pharmacy and gave the company a hold rating in a research note on Friday, February 22nd. Leerink Swann downgraded shares of Diplomat Pharmacy from an outperform rating to a market perform rating and set a $30.00 target price on the stock. in a research note on Monday, February 25th. Finally, Svb Leerink downgraded shares of Diplomat Pharmacy from an outperform rating to a market perform rating and reduced their target price for the company from $24.00 to $6.00 in a research note on Monday, February 25th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $10.25.

Shares of DPLO opened at $5.24 on Friday. Diplomat Pharmacy has a twelve month low of $4.99 and a twelve month high of $28.74. The firm has a market capitalization of $390.01 million, a PE ratio of 26.20 and a beta of 0.69. The company has a current ratio of 1.00, a quick ratio of 0.66 and a debt-to-equity ratio of 1.00.

Diplomat Pharmacy (NYSE:DPLO) last announced its earnings results on Tuesday, May 7th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.26). Diplomat Pharmacy had a negative net margin of 5.85% and a positive return on equity of 1.38%. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the company posted ($0.01) EPS. The company’s revenue was down 6.4% compared to the same quarter last year. On average, equities research analysts predict that Diplomat Pharmacy will post -0.53 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of the stock. Morgan Stanley increased its stake in Diplomat Pharmacy by 214.3% in the 1st quarter. Morgan Stanley now owns 330,133 shares of the company’s stock worth $1,918,000 after buying an additional 225,099 shares during the period. SEI Investments Co purchased a new position in Diplomat Pharmacy in the 1st quarter worth about $59,000. Ellington Management Group LLC purchased a new position in Diplomat Pharmacy in the 1st quarter worth about $127,000. Geode Capital Management LLC increased its stake in Diplomat Pharmacy by 9.2% in the 1st quarter. Geode Capital Management LLC now owns 653,680 shares of the company’s stock worth $3,797,000 after buying an additional 54,927 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Diplomat Pharmacy by 19.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 657,754 shares of the company’s stock worth $3,822,000 after buying an additional 108,531 shares during the period. 75.81% of the stock is currently owned by institutional investors.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

See Also: Initial Public Offering (IPO)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.